Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study

Fayad, Lea; Adam, Atif; Schweitzer, Michael; Cheskin, Lawrence J.; Ajayi, Tokunbo; Dunlap, Margo; Badurdeen, Dilhana; Hill, Christine; Paranji, Neethi; Lalezari, Sepehr; Kalloo, Anthony N.; Khashab, Mouen A.; Kumbhari, Vivek

doi:10.1016/j.gie.2018.08.030

Cited by 134 publications

(93 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although technically simple, safe, and effective for weight loss, sleeve gastrectomy is associated with increased health care utilization costs secondary to multiple known serious adverse events (SAEs), and increased prevalence of worsened or de novo GERD with unknown associated long-term risks of Barrett's esophagus and esophageal adenocarcinoma. 1 Given these limitations, particularly in patients with lower body mass index (between 30 to 40 kg/m 2 ), endoscopic sleeve gastroplasty (ESG) is an attractive minimally invasive endoscopic alternative to surgery that expands the therapeutic benefits of effective obesity interventions targeting the GI tract to patients who do not qualify for or wish to pursue bariatric surgery. 2 In the largest series of patients undergoing ESG to date, Alqahtani et al 3 add to a growing body of literature that suggests ESG is ready for prime time in the evolving management paradigm of obesity and metabolic disease.…”

mentioning

confidence: 99%

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Storm

Dayyeh

2019

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

mentioning

confidence: 99%

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Storm

Dayyeh

2019

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…The overall mean %TBWL at 12 months of the 121 patients that were treated in our center is in accordance with other studies (Table 1). 2,3,[6][7][8][9][10][11][12][13] As in all endoscopic procedures, ESG is repeatable per definition and the need to perform a redo ESG should not be considered as a failure of the previous procedure, but in selected patients it can be contemplated as a second-step endoscopic treatment approach. Indications for redo ESG are the same as for the first procedure.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5][6] The reported mean percentage of total body weight loss (%TBWL) is 17.2% at 12 months and 20.2% at 24 months, on average (Table 1). 2,3,[6][7][8][9][10][11][12][13] If weight resumption after surgery is considered a real failure of the technique, the need to perform a redo ESG in selected patients should not be considered as a failure of the previous procedure. ESG is repeatable per definition, likewise for every endoscopic procedure.…”

Section: Introductionmentioning

confidence: 99%

Redo endoscopic sleeve gastroplasty: technical aspects and short-term outcomes

Boškoski

Pontecorvi

Gallo

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Endoscopic sleeve gastroplasty (ESG) is a restrictive endoscopic bariatric procedure providing promising results. In this short case series, we analyze the technical aspects and short-term outcomes of the redo ESG. Methods: A retrospective analysis was done on a prospective database of all patients that were selected by a multidisciplinary team that underwent ESG between March 2017 and May 2019. Patients that underwent a redo ESG because of a progressive loss of satiety, weight regain, or insufficient weight loss due to high baseline body mass index were included. Percentage of excess weight loss (%EWL), percentage of total body weight loss (%TBWL), and the Bariatric Analysis and Reporting Outcome System (BAROS) questionnaire were evaluated during follow-up. Results: A total of 120 ESG procedures were performed with mean %EWL of 44.4% (± 19.5), mean %TBWL of 18.3% (± 6.7), and mean BAROS of 4.5 (± 1.7) at 12 months. Of those, four patients that underwent a redo ESG were identified. A total of three of them had a redo ESG after 12 months from the first ESG, whereas one of them had a redo ESG after 7 months. During the second procedure, old threads were removed with scissors and new stitches were positioned following a triangular pattern and avoiding overlap with the previous stitches. No adverse events were reported during the redo ESG. Six month follow-up was available for three patients, mean %EWL and %TBWL were 44.2% and 20.4%, respectively; BAROS questionnaire mean score was 6.3. One patient had only 1 month follow-up with a mean %EWL and %TBWL of 33.3% and 12.2%, respectively; BAROS questionnaire reported score was 6. All included patients reported excellent satiety feeling after redo ESG. Conclusions: The redo ESG short-term outcomes are completely satisfying in terms of safety and efficacy. The need to perform a redo ESG should not be considered as a failure of the previous procedure, but it can be considered as a second step of the endoscopic treatment strategy.

show abstract

“…ESG is now rapidly affirming as an effective alternative to LSG and there is initial evidence that it may be safer than LSG and effective in improving DM2, hypertension, reflux disease and obstructive sleep apnoea syndrome 28,29 . In the largest series described so far, including 1000 patients, ESG was well tolerated and effective in inducing significant weight loss without mortality or significant morbidity at 18‐month follow‐up 30 …”

Section: Endoscopic Sleeve Gastroplastymentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Salomone¹,

Sharaiha

Boškoski

2020

Liver International

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by noninvasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications. K E Y W O R D S bariatric endoscopy, duodenal mucosal resurfacing, endoscopic sleeve gastroplasty, intragastric balloon, NAFLD, obesity How to cite this article: Salomone F, Sharaiha RZ, Boškoski I. Endoscopic bariatric and metabolic therapies for nonalcoholic fatty liver disease: Evidence and perspectives. Liver

show abstract

Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study

Cited by 134 publications

References 20 publications

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Redo endoscopic sleeve gastroplasty: technical aspects and short-term outcomes

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Contact Info

Product

Resources

About